Imunon (NASDAQ:IMNN) Receives Buy Rating from HC Wainwright

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Several other analysts have also recently commented on IMNN. D. Boral Capital reiterated a “buy” rating and issued a $29.00 price target on shares of Imunon in a research note on Tuesday. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Stock Performance

IMNN stock opened at $0.90 on Wednesday. The company’s fifty day moving average price is $0.90 and its 200-day moving average price is $1.11. Imunon has a one year low of $0.48 and a one year high of $3.65. The company has a market capitalization of $13.04 million, a PE ratio of -0.48 and a beta of 2.12.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.